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OBJECTIVES The purpose of this study was to test the hypothesis that a subgroup of QW7437
microbubbles, dodecafluoropentane-based ultrasound contrast microspheres, resides for
prolonged periods in the microvasculature.
BACKGROUND QW7437 produces echo enhancement in myocardium which may persist relatively longer
than opacification in the left ventricular cavity. The mechanism for this persistent enhance-
ment remains unknown.
METHODS The transit of fluorescently labeled erythrocytes was examined by fluorescence intravital
microscopy in the microvessels in five rat mesenteries. Ten rats were used to observe the
behavior of fluorescently labeled QW7437 microbubbles in the mesenteric microcirculation.
RESULTS There was no significant change in erythrocyte velocity in the arterioles and venules after the
administration of QW7437 microbubbles (0.05 ml/kg) preactivated by negative hydrody-
namic pressure. Of 552 microbubbles observed in four arterioles and five capillaries, 549
(99.5%) passed without stoppage ($0.1 s stoppage); only one stopped transiently in arteriole
and two in capillaries, each for ,0.5 s. Sixty-five of 478 microbubbles (13.6%) observed in six
postcapillary venules 11 to 30 mm in diameter and 24 of 408 microbubbles (5.9%) in four
venules 31 to 50 mm in diameter stopped transiently (0.1 to 180 s) with an attachment to
venular endothelium; the remaining microbubbles passed through the venules without
stoppage.
CONCLUSIONS Prolonged survival as microbubbles in the circulation and transient stoppage of a subgroup of
microbubbles in the microvasculature, particularly in venules, are potential mechanisms for
the persistent tissue echo enhancement by QW7437 microbubbles during contrast echocar-
diography. (J Am Coll Cardiol 1999;34:578–86) © 1999 by the American College of
Cardiology
The development of new ultrasound contrast techniques
offers an opportunity to expand the application of echo-
cardiography in clinical cardiology (1–3). A number of
new ultrasonic contrast agents have recently been devel-
oped based upon the concept that extended stability of
microbubbles in blood would enable myocardial enhance-
ment to be achieved by intravenous administration (4 –7).
One of these agents, a dodecafluoropentane (DDFP)
emulsion which converts to a gas at body temperature
(37°C), yields enhancement of myocardium, kidney and
other organs, which is relatively unusual because it can
persist beyond left ventricular cavity opacification (4 –7).
The mechanism for the persistent gray-scale enhance-
ment of the tissue signal remains unknown. In fact,
limited data exist regarding the behavior of air-filled
ultrasound contrast microbubbles within the microcircu-
lation (8 –11).
We hypothesized that a subgroup of DDFP micro-
bubbles (QW7437) in vivo might remain in the normal
microvasculature longer than erythrocytes, especially at sites
with lower shear stress. To investigate this hypothesis we
serially observed the behavior of fluorescently labeled
QW7437 microbubbles and erythrocytes in mesenteric ar-
terioles, capillaries and venules of rats by intravital fluores-
cence microscopy.
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METHODS
Animal preparation. All animal procedures were reviewed
and approved by the University of California at San Diego
Animal Subjects Committee. Wistar rats (n 5 15, at 13 to
15 weeks of age, 280 to 400 g; Charles River Breeding
Laboratories, Wilmington, Massachusetts) were used for
the study. After general anesthesia with pentobarbital so-
dium (30 mg/kg IM), a catheter (PE-50 tubing, Clay
Adams, Parsippany, New Jersey) was inserted into the left
femoral artery and systemic blood pressure was continuously
monitored. Another catheter was inserted into the left
femoral vein. The animals were placed on a water heating
pad maintained at 37°C. The abdomen was opened by a
small midline incision and the ileocecal part of the mesen-
tery was carefully exteriorized and draped over a thin plastic
foil (Reynold’s Plastic Wrap, Richmond, Virginia) to min-
imize exposure to air and room temperature during intrav-
ital microscopy (12). The preparation was maintained at
37°C and continuously superfused (1.0 ml/min) with a
Krebs-Henseleit bicarbonate-buffered solution saturated
with a 95% N2 and 5% CO2 gas mixture to maintain
physiologic pH.
Intravital fluorescence microscopy and image analysis.
The mesenteric microcirculation was visualized through an
intravital fluorescence microscope (3 25, water-immersion
objective lens, Leitz, Wetzlar, Germany) with the use of a
silicone-intensified target tube camera (Series 66, Dage-
MTI, Michigan City, Indiana). To elicit fluorescent images,
the sample was illuminated with a 200-W mercury lamp.
The light was passed through a quartz collection, a heat
filter (Model KG-2; Carl Zeiss, Thornwood, New York)
and a 515- to 560-nm wavelength excitation filter (Leitz,
Rockleigh, New Jersey) to epi-illuminate the sample. Flu-
orescent emission from the selected area was passed through
a 580-nm thick bandpass filter (Leitz). Transillumination
was provided by a 250-W halogen light source with heat
filter. The video vertical frame rate of the camera was 30/s.
The overall magnification on the TV monitor was approx-
imately 3 910. The microscope was focused to limit the
observations to the median plane of the vessel of interest.
The images were stored on a videocassette recorder (Model
AG-6300, Panasonic, Tokyo, Japan) for off-line analysis.
All images were compiled and analyzed on a Macintosh
computer with public domain National Institutes of Health
image software (Version 1.60). The computer was calibrated
in the x-y planes using a calibration reticule (10-mm
divisions). The vessel diameters refer to inner lumen mea-
surements; no corrections were made for noncircular cross
sections (13). The velocity of labeled microbubbles and
erythrocytes in arterioles, capillaries and venules was mea-
sured twice with frame by frame analysis (9), and the two
measurements were averaged. We defined a transient stop-
page of microbubbles as stopping in the vessels persisting for
0.1 s (3 frames) or longer, and less than 3 min. The
frequency of microbubbles adhering to the endothelial cells
(EC) was determined by dividing the number of adhering
microbubbles per 200 mm length of each vessel by the total
number of microbubbles observed in that vessel.
Microbubble preparation. QW7437 (Sonus Pharmaceuti-
cals, Bothell, Washington) is a premixed liquid-in-liquid
emulsion of DDFP which converts to a gas at body tempera-
ture (37°C). The emulsion contains droplets with a mean
diameter of approximately 0.3 mm. On intravenous adminis-
tration, this liquid emulsion becomes a dispersion of micro-
bubbles with an average diameter of 2 to 5 mm and a mean
concentration of 1012 microbubbles/ml (4,6). The emulusion is
negatively charged to minimize adhesion of the microbubbles
to the vascular EC (5). The surface of QW7437 was labeled by
a fluorescent dye PKH-26 (Zynaxis Cell Science, Malvern,
Pennsylvania) (Fig. 1), a label for cell membrane lipids (14–
17). To observe the microbubbles in vivo, the following
fluorescent labeling technique was used: 1) a 1023-mol/liter
stock solution of the fluorescent dye PKH-26 was added to the
emulsions of QW7437 for a final PKH-26 concentration of
5 3 1026 mol/liter; 2) the mixtures were gently stirred in the
dark for 5 min at room temperature; 3) after drawing 1 ml of
labeled or nonlabeled QW7437 into a 30-ml syringe with a
stopcock, a negative hydrodynamic pressure was manually
imposed on the QW7437 by pulling back the plunger abruptly
to the 10-ml line, then releasing it immediately to convert
some of the QW7437 emulsion from liquid to gas before
intravenous administration (7,18,19); 4) to stop the staining
reaction, 1 ml rat plasma was added to the PKH-26 with
QW7437 mixtures and gently mixed for 1 min. The mixtures
were drawn into a 1-ml syringe for injection. For all injections,
the QW7437 emulsion was administered as soon as possible
after application of the negative hydrodynamic pressure. In a
preliminary study, myocardial contrast echocardiography
(MCE) by intravenous injection of 0.05 ml/kg of PKH-labeled
Abbreviations and Acronyms
DDFP 5 dodecafluoropentane
EC 5 endothelial cells
MCE 5 myocardial contrast echocardiography
Figure 1. Two QW7437 microbubbles labeled by PKH-26 under
transillumination (left panel) and their fluorescent image (right
panel).
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QW7437 preactivated by negative hydrodynamic pressure
showed similar intensity and duration of myocardial enhance-
ment in rats as 0.05ml/kg of nonlabeled QW7437 (data not
shown). This finding supports the concept that PKH staining
does not change the echogenicity of QW7437 microbubbles.
Microbubble size in vitro. An in vitro study was carried
out to assess the effect of the body temperature (37°C) on
the size distribution of QW7437 microbubbles. Fresh hu-
man venous blood was drawn by a clean venipuncture of an
anticubital vein of a healthy volunteer into a plastic syringe
containing ethylenediaminetetraacetic acid–2Na (1 mg/ml)
with a pressure-resistant stopcock just before the experi-
ment. Special attention was taken not to expose the sampled
blood to the air. Labeled QW7437 (0.05 ml) after the
application of negative pressure was mixed with 2 ml of the
fresh human blood at 37°C in a 3-ml syringe with a
stopcock. The syringe was gently and continuously rotated
in a water bath at 37°C for 60 s. Slide glasses were warmed
on a heating pad at 37°C until microbubbles were placed on
them. Then one drop of the mixture was immediately
placed on a glass slide with a coverslip. Microbubble sizes
were observed using microscopy (3 40, water-immersion
objective lens, Leitz, Wetzlar, Germany). The images were
recorded with a color CCD (coupled charge device) camera
(DEI-470, Optonics, Goleta, California) and stored on
VHS tape using the videocassette recorder (Panasonic,
Tokyo, Japan) within 60 s after placing the microbubbles on
the glass slide. The diameters of 500 microbubbles were
measured by off-line analysis using National Institutes of
Health image software as described above. The overall
magnification on the TV monitor for these measurements
was approximately 3 2,000. To get control values before
mixing with blood, one drop of labeled QW7437 solution
after the application of negative pressure was placed on a
glass slide with a coverslip.
In vivo protocol 1. Five Wistar rats were used for protocol
1 to serially measure the velocity of fluorescently labeled
erythrocytes in the mesenteric microcirculation before and
for 10 min after the intravenous administration of
QW7437. Erythrocytes from separate donor rats were
labeled with PKH-26 according to the manufacturer’s
instructions. PKH-labeled erythrocytes are stable in vivo
(14–16). This enhanced stability allowed us to determine
the erythrocyte velocity in vivo throughout the 10-min
course of the experiment after a single bolus injection.
Injection of 0.1 ml of PKH-labeled erythrocytes was carried
out via the left femoral vein. After recording a control
image, 0.05 ml/kg of nonlabeled QW7437 treated with the
negative hydrodynamic pressure (5,20) was immediately
mixed with 0.2 ml whole blood drawn from the femoral
vein, and injected over a 15-s period via the femoral vein.
The catheter was flushed with 0.25 ml saline after each
injection.
A selected tissue area was recorded under fluorescent
microscopy for 1 min after the onset of the QW7437 bolus
injection, and for periods of 50 s each at 2, 5 and 10 min
after the injection. Five arterioles with diameters between
11 and 30 mm and four venules with diameters between 25
and 50 mm were recorded for analysis. After the recording
of each fluorescent image, transillumination images were
obtained for off-line measurements of vessel diameters.
In vivo protocol 2. Ten Wistar rats were used for protocol
2 to determine whether vascular obstruction or transient
stoppage of QW7437 microbubbles with attachment to
microvascular EC occurred or not. Of the mixtures contain-
ing 0.05 ml/kg of labeled QW7437 after application of the
negative pressure, 0.1 ml/kg was injected over a 15-s period
via the left femoral vein in the same way as described in
protocol 1. Only one bolus of QW7437 was administered to
each rat. Fluorescent images of selected tissue areas were
recorded continuously for 10 min after the injections. Four
arterioles examined ranged in diameter between 13 mm and
29 mm, five capillaries in diameter between 5 mm and 8 mm
and 10 venules in diameter between 11 mm and 50 mm.
When microbubbles stopped in vessels for more than 2 s, we
simultaneously switched to semibright field for a few sec-
onds, to determine whether vascular obstruction occurred or
not. We skipped this semibright field observation when the
other microbubbles passed by retained microbubbles in
venules, because this passing phenomenon clearly demon-
strates QW7437 microbubble attachment to EC without
obstruction. Fifteen minutes after QW7437 injection,
0.1-ml PKH-labeled erythrocytes were injected in two rats
into the left femoral vein to compare the velocities of
microbubbles and erythrocytes in individual venules with
diameters of 12 mm, 13 mm and 44 mm.
Statistics. All results are expressed as means 6 SD. Time
course of labeled erythrocyte velocities (maximum and
mean) and vessel diameter in protocol 1 and systolic blood
pressure data in protocol 2 were assessed by one-factor
analysis of variance for repeated measures. Velocities of the
labeled microbubbles was compared with those of labeled
erythrocytes in individual venules by unpaired Student t test.
Frequency of transiently adhering microbubbles was com-
pared between arterioles, capillaries and venules by chi-
square or Fisher exact probability test for group data.
Probability levels of less than 0.05 were considered to be
statistically significant. The statistical analysis was carried
out with Stat View IV software (Abacus Concepts, Berke-
ley, California).
RESULTS
Microbubble size in vitro. The in vitro QW7437 diameter
of 500 microbubbles immediately after the application of
negative pressure was 5.4 6 2.6 mm (mean 6 SD), 4.8 mm
(median), 2.5 mm (10th, percentile), 8.0 mm (90th, percen-
tile) with a range between 1 and 22 mm and 4.4% of
microbubbles larger than 10 mm in diameter. After mixture
with human blood at 37°C for 1 min, the QW7437
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diameter was increased to 5.9 6 5.2 mm (mean 6 SD, p ,
0.05 vs. before mixing with human blood at 37°C(n 5 335),
3.5 mm (median), 2.0 mm (10th, percentile), 12.0 mm (90th
percentile) with a range between 1 and 34 mm and 12.4% of
microbubbles larger than 10 mm in diameter.
In vivo protocol 1. A summary of the velocity data of
labeled erythrocytes and measurement of vessel diameter is
presented in Table 1. More than 50 labeled erythrocytes
were visible and assessed in every vessel of interest during
each examination period. There was no significant change
in erythrocyte velocity in each vessel after the administration
of QW7437 compared with the erythrocyte velocity before
the administration. No labeled erythrocytes adhered to the
vessels. The diameters of the arterioles and venules re-
mained unchanged.
In vivo protocol 2. Neither tachypnea (not quantified) nor
significant change in systolic blood pressure or heart rate
over time was observed during protocol 2 (before adminis-
tration, 130 6 13 mm Hg, 342 6 39 beats/min; 30 s after
administration, 128 6 13 mm Hg, 343 6 29 beats/min; at
1 min, 131 6 15 mm Hg, 341 6 33 beats/min; at 5 min,
128 6 13 mm Hg, 335 6 32 beats/min, and at 10 min,
126 6 17 mm Hg, 337 6 35 beats/min).
More than 50 labeled microbubbles (about 3 3 1027% of
intravenously injected microbubbles) were observed within
each observation field after each injection. Several micro-
bubbles could be visualized in the microvasculatures for
periods of 5 min after administration. In four arterioles, 399
out of 400 microbubbles passed rapidly through arterioles
without transient stoppage during a period of 10 min after
the injection (Fig. 2A and 3), and only one microbubble
(0.25%) transiently stopped in an arteriole for 0.27 s. The
velocity of QW7437 microbubbles in arterioles (n 5 400,
3.59 6 1.93 mm/s, p 5 0.41) was not significantly different
from that of labeled erythrocytes in arterioles after admin-
istration of the agent in protocol 1 (n 5 257, 3.70 6
1.16 mm/s). Among a total of 152 microbubbles observed in
capillaries, 150 microbubbles flowed freely through five
capillaries without transient stoppage (Fig. 2B and 3). Only
two microbubbles (1.3%) were observed to be transiently
stopped on capillary EC for less than 0.5 s. Unfortunately
we could not observe the passing phenomenon or persistent
Figure 2. The time course of individual QW7437 microbubble
velocities in four arterioles (a), vessel diameter between 13 mm and
29 mm) and in five capillaries (b), vessel diameter between 5 mm
and 8 mm). Open squares show microbubbles with a transient
stoppage ($0.1 s stoppage at one site), and small closed squares
show microbubbles without it. In a, only one microbubble showed
a stoppage for 0.27 s to a terminal arteriole at 465 s after the
administration. In b, two microbubbles showed a transient stop-
page in capillaries for 0.37 s and 0.40 s, respectively.
Table 1. Velocity of Labeled Erythrocytes and Vessel Diameter in Arterioles and Venules Before and After Administration of
QW7437 (0.05 ml/kg)
Time after
Administration
Arterioles (11–30 mm) (n 5 5) Venules (25–30 mm) (n 5 4)
Vmax
(mm/s)
Vmean
(mm/s)
Vessel
Diameter (mm)
Vmax
(mm/s)
Vmean
(mm/s)
Vessel
Diameter (mm)
Before 4.84 6 1.25 3.80 6 1.04 16 6 6 2.66 6 0.38 1.67 6 0.28 41 6 8
0–1 min 4.72 6 1.19 3.63 6 1.19 16 6 6 2.65 6 0.28 1.82 6 0.25 41 6 8
2–3 min 4.34 6 1.17 3.59 6 0.98 16 6 6 2.48 6 0.26 1.81 6 0.31 40 6 8
5–6 min 4.21 6 1.02 3.39 6 0.87 16 6 5 2.45 6 0.57 1.76 6 0.37 41 6 8
10–11 min 4.74 6 1.13 3.48 6 0.73 16 6 5 2.72 6 0.05 1.79 6 0.12 42 6 9
p value 0.49 0.44 0.89 0.43 0.53 0.79
All values are expressed as means 6 SD.
Vmax 5 maximum velocity of erythrocytes at the center of each vessel; Vmean 5 mean velocity of erythrocytes in each vessel.
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blood flow in semibright field when the three microbubbles
showed transient stoppage in arterioles and a capillary.
Transient stoppage of microbubbles occurred more fre-
quently in venules than in arterioles or capillaries (p ,
0.0001). When microbubbles stopped in venules for more
than 2 s, semibright field showed persistent erythrocyte flow
in all of these particular venules. The venules examined
ranged in diameter between 11 and 50 mm, and were
subdivided into those #30 mm and those .30 mm. Tran-
sient stoppage occurred more frequently in smaller venules
with diameters between 11 mm and 30 mm (13.6%, p ,
0.001, Fig. 4A and 5) than in larger venules with diameters
between 31 mm and 50 mm (5.9%, Fig. 4B). The adhering
microbubbles remained stationary at one site for periods
ranging from 0.1 s to 120 s (Table 2). Among the set of
stopping bubbles, 60 microbubbles (65.2%) were attached to
venular EC for more than 1.0 s and only six microbubbles
(6.5%) were stationary for more than 60.0 s. The diameter
of the fluorescent microbubble images which stopped in
venules and remained in sharp focus on still frame review
was 6.4 6 1.2 mm (n 5 69). Their size remained unchanged
during the period of stoppage. No microbubbles showed
permanent stoppage (.3 min) or extravascular emigration
in the selected observation areas.
Microbubble velocity relative to that of erythrocytes
varied among individual venules. In venule ’1 (vessel
diameter of 12 mm) and ’2 (vessel diameter of 13 mm) in
Table 2, velocities of labeled QW7437 microbubbles
(venule ’1: 0.88 6 0.67 mm/s, n 5 73; venule ’2: 0.91 6
0.55 mm/s, n 5 84) were significantly slower (p , 0.05)
than those of erythrocytes (venule ’1: 1.14 6 0.55 mm/s,
n 5 50; venule ’2: 1.13 6 0.4 mm/s, n 5 68). In venule
’8 (vessel diameter of 44 mm), however, velocities of
labeled QW7437 microbubbles (1.58 6 0.72 mm/s, n 5
107, p 5 0.1) were not significantly different from those of
Figure 3. A fluorescently labeled QW7437 microbubble moving
along an arteriole and capillary. An arteriole with a diameter of
19 mm, branching into an 18-mm arteriole and a 10-mm arteriole
turning into a 7-mm capillary, was imaged under transillumination
in A. The flow in the arteriole is from right to left. In B, a
PKH-26–labeled QW7437 microbubble was moving through the
arteriole at 60 s after the bolus injection. C shows the image of the
bubble entering into the capillary at 0.07 s after B. In D, the
bubble was moving along the capillary without stoppage at 0.13 s
after B.
Figure 4. The time course of individual QW7437 microbubble
velocities in six venules with a vessel diameter between 11 mm and
30 mm (a) and in four venules with a vessel diameter between
31 mm and 50 mm (b). Open squares show microbubbles with
transient stoppage ($0.1 s stoppage at one site), and small closed
squares show microbubbles without transient stoppage.
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erythrocytes (1.74 6 0.60 mm/s, n 5 90). When the
velocity of labeled erythrocytes in 25- to 50-mm venules
(n 5 412, 1.82 6 0.55 mm/s) after administration of
nonlabeled QW7437 in protocol 1 was compared with the
velocity of QW7437 microbubbles in similar size venules in
protocol 2, the latter was significantly slower (n 5 485,
1.10 6 0.80 mm/s, p , 0.001).
DISCUSSION
The present measurements document for the first time the
rheologic characteristics of DDFP ultrasound contrast mi-
crobubbles in the microcirculation using a fluorescence
intravital microscopic approach. The data demonstrate that,
after injection of a clinical dose of QW7437, erythrocyte
velocity is unaltered in arterioles and venules in the presence
of the microbubbles, and transient stoppage of microbubbles
occurs rarely in arterioles and more frequently in venules.
Microbubble life span in vivo. QW7437 microbubbles
were observed in the circulation, including arterioles, for
periods up to 5 min after administration. This represents a
longer period of stability than that seen with sonicated
albumin microbubbles, which become invisible in the cheek
pouch microcirculation of hamsters (9) and in the mesentery
microcirculation of rats (unpublished data) within 2 min of
intravenous administration. The potential mechanisms by
which QW7437 microbubbles persist in blood and provide
longer acoustic contrast than air or carbon dioxide micro-
bubbles include: 1) DDFP has a much lower solubility in
water than oxygen or nitrogen; 2) it has slower diffusion in
blood because of its larger molecular weight (228 D); 3) it
has a low concentration of saturation in blood, and 4) it
Figure 5. Sequence of micrographs showing the process of attachment of fluorescently labeled QW7437 microbubbles to the
postcapillary venules. The flow is from top to bottom right. A: A 12-mm postcapillary venule indicated by an arrow running on the
right side of a 48-mm collecting venule under transillumination. B: Two microbubbles showed transient stoppage to a 12-mm
postcapillary venule 150 s after the labeled QW7437 bolus injection. C: 1.0 s after B. The right microbubble (small arrow) moved
as slowly as 15 mm in 1.0 s; however, the left microbubble (large arrow) remained at the same site. D: 5.0 s after B. The right
microbubble (small arrow) moved away after stopping for 4.0 s at the same locale shown in C. The left microbubble (large arrow)
stayed at the same site as shown in B. E: 5.07 s after B. The microbubble. (large arrow) has started to move again after stopping
for 5.1 s.
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contains carbon–fluorine bonds which are not metabolized
in the body but are excreted through the lung (6,7).
Microbubble velocity and transient adhesion to the en-
dothelium. Keller et al. (9) have reported that sonicated
albumin microbubbles showed a velocity profile similar to
that of erythrocytes in the cheek pouch microcirculation of
hamsters. They simultaneously measured the velocities in
arterioles of sonicated albumin microbubbles labeled with
dichlorotriazinylaminofluorescein-1-dihydrochloride and
calcein-labeled erythrocytes using intravital fluorescence
microscopy equipped with a strobe illuminator. We mea-
sured the velocity of labeled erythrocytes and microbubbles
in separate protocols, since preliminary experiments had
shown that it was difficult to distinguish PKH-labeled
erythrocytes from PKH-labeled microbubbles in vivo.
The slow intravenous injection of 0.05 ml/kg preactivated
QW7437 microbubbles over 15 s did not produce a change
in systemic blood pressure and heart rate. In addition, this
clinical dose of QW7437 neither changed the vessel diam-
eters of arterioles or venules, nor altered erythrocyte veloc-
ities in arterioles and venules. These results are consistent
with the previous reports (18,19).
In vitro results showed a heterogeneous growth of
QW7437 microbubbles after 1 min mixture with blood at
37°C. However, no obstruction was seen with QW7437
microbubbles in arterioles and capillaries in the mesenteric
microcirculation. Obviously, microbubbles are subjected to
different pressures in vitro than in vivo. In addition, after
intravenous injection, microbubbles, (which are significantly
larger than the pulmonary capillary vessel diameters) may be
filtered by the pulmonary microcirculation, despite the fact
that some small bubbles have a potential to grow after
passing through the pulmonary microcirculation. The di-
ameters of the transiently stopped QW7437 microbubbles’
images remained unchanged during stoppage and were
slightly larger than the mean bubble size measured in vitro,
although QW7437 bubbles which stopped in venules for a
longer duration exhibited fluorescent quenching (loss in
fluorescent brightness). Beppu et al. (6) have reported that
an alternate DDFP-based agent, QW3600, can result in
microbubbles as large as three to eight times the size of an
erythrocyte in both an arteriole and a venule in rat mesen-
tery, and can induce a gradual slowing and stoppage of
blood flow. However, these observations were made after
intravenous administration of QW3600 in doses that were
much greater (2 to 4 ml/kg) than those used for QW7437,
and were given without the application of negative pressure
as used in this study. In recent clinical trials (7) in which
QW3600 has been given in lesser doses (0.1 ml/kg or less)
after hydrodynamic preactivation, the duration of contrast
opacification has been substantially shorter than that re-
ported in the animal studies without hydrodynamic preac-
tivation technique (6). In addition, the negative electrical
charge on QW7437 to some extent inhibits microbubble
attachment to the vascular EC (19). Beppu et al. (6) and
Main et al. (19) have suggested that the long residence of
some microbubbles in microvessels with obstructed blood
flow represented a possible explanation for the prolonged
myocardial opacification by DDFP microbubbles. Our re-
sults suggest that long residence of some microbubbles in
venules without obstructed blood flow also contributes to
prolonged myocardial opacification.
The velocities of QW7437 microbubbles were signifi-
cantly slower and manifested a wider spectrum of values
than labeled erythrocytes in the venules with diameters of
12 mm and 13 mm. This difference in axial velocities was
likely caused by the transient stoppage of some micro-
bubbles at venular EC. A previous study (9) also reported
that a few sonicated albumin microbubbles were observed to
adhere to the EC of collecting venules. The interaction of
erythrocytes with the relatively large microbubbles in capil-
laries and venules appears to resemble that of erythrocytes
with leukocytes (21,22). Adhesion molecules on EC may
have a role in the overall process of attachment (22–25). Iigo
et al. (25) have reported that postcapillary venular EC are
the major portion expressing intercellular adhesion
Table 2. Velocity and Transient Stoppage Frequency of Labeled Microbubbles in Venules
No.
Venular
diameter
(mm)
Vmax
(mm/s)
Vmean 6 SD
(mm/s) Vmax/Vmean
Frequency of
Transient
Stoppage
(>0.1 s) (%)
Mean and Range
of Stoppage
Duration (s)
1 12 2.88 0.88 6 0.67 3.27 22.2 16.0 (0.1–60.0)
2 13 2.22 0.91 6 0.55 2.44 19.0 6.8 (0.2–64.0)
3 15 1.20 0.74 6 0.32 1.62 23.0 1.4 (0.1–6.0)
4 17 4.20 1.07 6 0.65 3.92 8.0 4.7 (0.1–30.0)
5 20 2.70 0.85 6 0.51 3.18 6.3 6.0 (2.1–10.0)
6 25 2.04 0.93 6 0.45 2.19 11.1 0.4 (0.1–1.1)
7 32 1.35 0.85 6 0.51 1.59 9.7 23.3 (0.1–120.0)
8 44 3.00 1.58 6 0.72 1.90 4.6 6.9 (0.2–19.0)
9 48 2.67 1.35 6 0.84 1.98 6.1 5.6 (0.1–11.0)
10 49 3.70 1.24 6 0.88 2.98 6.0 0.8 (0.1–4.0)
Vmax 5 maximum velocity of labeled microbubbles at the center of each vessel; Vmean 5 mean velocity of the microbubbles in each vessel.
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molecule-1 among arterioles, capillaries and venules in the
rat mesentery. Further research is needed to explore the
molecular mechanisms for the phenomenon of microbubble
adhesion to the vessel EC.
Clinical implications. The primary goals of MCE are to
enhance endocardial border definition and achieve myocar-
dial opacification by intravenous injection. Dodecafluoro-
pentane microbubbles may serve this purpose. Previous
reports have shown that MCE performed with intravenous
administration of DDFP microbubbles permits the defini-
tion of myocardial area at risk and infarct size in a canine
model of regional myocardial ischemia (4–6, 19), and can
enhance left ventricular endocardial delineation in humans
(7,18). It may also be possible to apply indicator dilution
techniques to quantitate coronary blood flow by MCE (26).
Considering the retention of some DDFP microbubbles in
venules, we could not simply use these methods with these
agents to quantify coronary blood flow. Prolongation of
contrast enhancement may be of clinical value in overcom-
ing problems of signal attenuation associated with contrast
echo, and in enabling sufficient time for multiple view
examination. Perfluorocarbons have been applied as blood
substitutes because of their strong oxygen-binding capacity
and their high tolerance in mammals (27).
Experimental limitations. Several factors may have influ-
enced the results of this study. The microvascular structure
of the mesentery is not the same as in the myocardium or
other organs in terms of the size and density of capillaries
(28–30). Because it is still difficult to obtain continuous
observations of the myocardial microcirculation in vivo (31),
we selected a mesentery preparation allowing high resolu-
tion microvascular visualization that was essential for con-
tinuous and quantitative study of microbubble kinetics (28).
In an in situ rat heart study (29), subepicardial capillary
mean diameter has been found to be about 4 mm during
systole and about 5 mm during diastole. The range of the
mesentery capillary diameter examined in the present study
was from 5 mm to 8 mm with a mean value of 6.2 mm. From
this point of view, although no obstruction was seen with
QW7437 microbubbles in mesenteric capillaries, relatively
large bubbles may have a potential to transiently or per-
manently occlude smaller sized capillaries in the myocar-
dium (7).
Although microbubble size in vivo is an important factor
governing their kinetics in the microcirculation, such mea-
surements were not carried out in our experiment except on
adhering microbubbles. It was not possible to obtain accu-
rate measurements of microbubble size in vivo from images
of fluorescently labeled bubbles moving in vessels.
In conclusion, the velocity of the QW7437 microbubbles
during their movement in postcapillary venules is different
from that of the erythrocytes. About 10% of the micro-
bubbles transiently stopped with an attachment to venular
EC. The relatively long stability of microbubbles in the
circulating blood and their extended residence in venules are
potential mechanisms for the more persistent myocardial
wall enhancement that may be seen with QW7437 micro-
bubbles in contrast echocardiography.
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